Rhumbline Advisers Kronos Bio, Inc. Transaction History

Rhumbline Advisers

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$1.23 - $2.25 $5,126 - $9,378	-4,168 Reduced 66.62%	2,088 $2,000
Q2 2023 Aug 08, 2023	SELL	$1.24 - $1.92 $69,319 - $107,333	-55,903 Reduced 89.94%	6,256 $10,000
Q1 2023 May 11, 2023	BUY	$1.34 - $2.62 $1,137 - $2,224	849 Added 1.38%	62,159 $91,000
Q4 2022 Feb 14, 2023	BUY	$1.44 - $3.44 $116 - $278	81 Added 0.13%	61,310 $99,000
Q3 2022 Nov 10, 2022	BUY	$3.35 - $5.55 $16,662 - $27,605	4,974 Added 8.84%	61,229 $205,000
Q2 2022 Aug 11, 2022	BUY	$3.12 - $7.52 $23,484 - $56,603	7,527 Added 15.45%	56,255 $205,000
Q1 2022 May 12, 2022	SELL	$6.26 - $14.42 $16,632 - $38,313	-2,657 Reduced 5.17%	48,728 $352,000
Q4 2021 Feb 10, 2022	SELL	$11.35 - $21.18 $6,855 - $12,792	-604 Reduced 1.16%	51,385 $698,000
Q3 2021 Nov 12, 2021	BUY	$18.17 - $24.7 $31,670 - $43,052	1,743 Added 3.47%	51,989 $1.09 Million
Q2 2021 Aug 05, 2021	BUY	$20.08 - $29.02 $703,924 - $1.02 Million	35,056 Added 230.78%	50,246 $1.2 Million
Q1 2021 May 06, 2021	BUY	$27.0 - $32.48 $54,918 - $66,064	2,034 Added 15.46%	15,190 $445,000
Q4 2020 Feb 10, 2021	BUY	$26.68 - $38.23 $351,002 - $502,953	13,156 New	13,156 $393,000

19.8M

9.3K

100

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $53.9M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.